Moderna Inc. and Merck & Co. announced that their personalized mRNA cancer vaccine successfully reduced the recurrence of melanoma in a large, late-stage clinical trial. The vaccine, when administered alongside Merck’s immunotherapy drug Keytruda, proved more effective in preventing the cancer's return after surgical removal than Keytruda alone, and also slowed its spread to other parts of the body. This success has raised considerable hope for the treatment of melanoma, the deadliest form of skin cancer, and validated the potential of mRNA technology in cancer therapy.
The positive trial results triggered a dramatic response in the stock market. Moderna's shares experienced an unprecedented surge, climbing as much as 177% on Wednesday, reaching $174.38. Merck's shares also saw a significant boost, rising by 10.6% to $149.52. This financial reaction underscores the market's strong confidence in the vaccine's future commercial prospects.
Analysts have reacted very positively to the news. TD Cowen analyst Tyler Van Buren called the outcome a "landmark moment." Jefferies analyst Andrew Tsai projected that the vaccine could generate billions of dollars in sales from melanoma treatment alone. Barclays, for instance, estimates the therapy could achieve approximately $3 billion in melanoma sales by 2035. The companies plan to release more detailed data at an upcoming medical meeting, and are also investigating the treatment's efficacy in other cancer types, including lung, kidney, and bladder cancers.
